Here you will find all the research and views that we post on Equitymaster. Use the tools to customize the results to suit your preference!
Dabur India, the ayurvedic products major, has reported a marginal 2% topline growth during the September quarter 2002. The company had reported a 7% topline growth during the June quarter. Cost efficiencies led to a 160 basis point expansion in operating margins, thus helping the company report nearly 24% growth in 2QFY03 net profit.
Dabur India, the ayurvedic products major, has reported an encouraging 7% topline growth in June quarter. It ability to control costs led to a 100 basis point expansion in operating margins, thus helping the company report an over 30% growth in 1QFY03.
Slowdown and competition seems to have finally caught with Dabur Limited, India's largest ayurvedic FMCG company. In 4QFY02, the company actually reported an 8% decline in topline (the first negative in last few years). Its net profit saw a 67% decline during the said quarter.
Dabur India Limited, the ayurvedic products major, reported a marginal 1% increase in topline and a mere 2% growth in net profits during the December quarter of FY02.
Dabur India declared its first half FY02 results yesterday. The company reported a small 3% growth in turnover and a 13% growth in bottomline during this period. Comparing 2QFY02 with the corresponding quarter last year, Dabur managed a 5% growth in turnover and a 10% growth in net profits.
Dabur India has posted a 23% growth in 1QFY02 net profit to Rs 88 m. This growth in bottomline has come despite a negligible topline growth. Reduction of interest cost by 8% and an 11% jump in other income contributed to the company's bottomline growth.
Dabur India, the ayurvedic products giant has declared a 42% jump in its 3QFY01 bottomline. This surge was on the back of a 10% jump in its topline during the period.
Dabur India, the 115 year old FMCG ‘ayurvedic’ company operates in the niche natural/ayurvedic products segment with a product folio of over 500 products. But despite its range, investors have been wary of investing in this company simply because of its unrelated diversifications and a family run business.
To a layman Dabur and Zandu are companies operating in the niche ayurveda segment. At first glance these companies seem alike because of their 'ayurvedic' image. But probe a little further and you find two very different entities.
Zandu's turnover has declined 16.6% while the net profits have declined by 21%. The company has been sucessful in mainting its operating margins.
A possible merger between the two ‘Chyavanprash’ giants Dabur and Zandu is brewing. Dabur has reportedly offered the Zandu management a price of Rs. 6800-7000 per share. Both the management’s have however denied the talks.
Zandu Pharmaceuticals has posted a 26% decline in net during the quarter ended 30th September 1999. The company has been adversely affected by the sharp jump in interest and depreciation expenditure.